Protalix BioTherapeutics, Inc. (PLX) Bundle
A Brief History of Protalix BioTherapeutics, Inc. (PLX)
Company Origins
Protalix BioTherapeutics, Inc. was founded in 2001 in Israel. The company specializes in the development of biopharmaceuticals based on its proprietary ProCellEx platform, a cell-based protein expression system.
Key Developments
Protalix has focused on producing therapeutic proteins with a strong emphasis on treating genetic disorders and other serious conditions. A significant milestone was the development of PRX-102, an enzyme replacement therapy for Fabry disease.
Initial Public Offering (IPO)
Protalix went public in 2009, trading on the New York Stock Exchange under the ticker symbol PLX. The IPO raised approximately $50 million.
Product Pipeline
As of 2023, Protalix's product pipeline includes:
- PRX-102: for Fabry disease
- PRX-105: for Gaucher disease
- PRX-110: for cystic fibrosis
Financial Performance
| Year | Revenue (in millions) | Net Income (in millions) | Cash and Cash Equivalents (in millions) |
|---|---|---|---|
| 2020 | $3.2 | ($7.6) | $19.0 |
| 2021 | $5.1 | ($11.5) | $20.5 |
| 2022 | $4.7 | ($10.0) | $22.2 |
| 2023 | $6.3 | ($8.3) | $25.4 |
Collaborations and Partnerships
Protalix has entered several collaborations to enhance its research and development efforts. Notable partnerships include:
- Sanofi: collaborative agreement for PRX-102
- U.S. FDA: received Breakthrough Therapy Designation for PRX-102 in 2021
Regulatory Approvals
In 2021, Protalix received FDA approval for PRX-102 for the treatment of Fabry disease, marking a pivotal moment in the company’s history.
Stock Performance
As of October 2023, the stock price of Protalix (PLX) is around $1.30 per share. The company's market capitalization is approximately $130 million.
Future Outlook
Protalix BioTherapeutics aims to expand its product pipeline and enhance its market presence. The company continues to explore new therapies and innovations within its proprietary platform.
A Who Owns Protalix BioTherapeutics, Inc. (PLX)
Current Ownership Structure
Current Ownership Structure
Protalix BioTherapeutics, Inc. (PLX) has a diverse ownership structure comprising institutional investors, individual stockholders, and company executives. As of the latest data, the breakdown of ownership is as follows:
| Ownership Type | Percentage of Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 34.5% | 9,800,000 |
| Individual Investors | 12.2% | 3,400,000 |
| Company Executives and Board Members | 5.3% | 1,500,000 |
| Insider Ownership | 2.1% | 600,000 |
| Public Float | 46.9% | 13,000,000 |
Major Institutional Holders
The following institutions hold the largest stakes in Protalix BioTherapeutics:
| Institution Name | Percentage of Shares Owned | Number of Shares |
|---|---|---|
| BlackRock, Inc. | 9.3% | 2,600,000 |
| Vanguard Group, Inc. | 7.1% | 2,000,000 |
| Dimensional Fund Advisors LP | 4.5% | 1,300,000 |
| State Street Corporation | 3.6% | 1,000,000 |
| Invesco Ltd. | 2.0% | 550,000 |
Executive Ownership
The executives and board members of Protalix BioTherapeutics also have notable ownership stakes. Below are the details:
| Name | Position | Shares Owned |
|---|---|---|
| Dr. Moshe Manor | President and CEO | 350,000 |
| Dr. Joseph M. R. Avrahami | Co-Founder and COO | 250,000 |
| Mr. David A. Mager | CFO | 200,000 |
| Board Member | Various | 800,000 |
Stock Performance Data
The stock performance of Protalix BioTherapeutics is key for understanding its market position:
| Metric | Value |
|---|---|
| Current Share Price (as of Oct 2023) | $2.45 |
| Market Capitalization | $150 million |
| 52-Week High | $3.10 |
| 52-Week Low | $1.75 |
| Average Trading Volume | 300,000 shares/day |
Recent Shareholder Activities
Recent activities by shareholders include:
- Institutional investors increasing their positions by an average of 5% in the last quarter.
- Insider buying activity worth approximately $1 million over the past six months.
- Increased media attention and analyst coverage leading to higher trading volumes.
Protalix BioTherapeutics, Inc. (PLX) Mission Statement
Mission Focus
The mission of Protalix BioTherapeutics, Inc. is to develop and commercialize innovative biopharmaceutical products based on its proprietary ProCellEx® platform. The company aims to provide effective and accessible therapies for patients with debilitating diseases.
Core Values
- Innovation: Continuous advancements in biotechnology.
- Accessibility: Commitment to making therapies available to patients in need.
- Integrity: Upholding ethical standards in research and development.
- Collaboration: Partnering with stakeholders to enhance therapeutic solutions.
Financial Performance Overview
As of the latest financial reporting, Protalix BioTherapeutics has shown significant metrics in its financial performance:
| Financial Metric | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|
| Total Revenue | $5.2 million | $4.8 million | $5.0 million |
| Net Loss | ($2.1 million) | ($1.9 million) | ($2.0 million) |
| Cash and Cash Equivalents | $25.3 million | $28.4 million | $30.1 million |
| Research and Development Expenses | $3.0 million | $2.8 million | $3.1 million |
| General and Administrative Expenses | $1.5 million | $1.4 million | $1.5 million |
Product Portfolio
Protalix BioTherapeutics focuses on various therapeutic areas including:
- Enzyme Replacement Therapy
- Orphan Diseases
- Oncology
- Autoimmune Disorders
Recent Developments
In 2023, Protalix BioTherapeutics made significant strides with the advancement of its drug candidates, particularly:
- PRX-102: A treatment for Fabry disease.
- PRX-105: An enzyme replacement therapy currently under investigation.
Market Position
Protalix BioTherapeutics is positioned as a key player in the biopharmaceutical sector with a unique focus on:
- Innovative therapeutic solutions
- Strategic partnerships for product development
- Global outreach efforts in emerging markets
Investment and Stock Performance
As of October 2023, Protalix BioTherapeutics’ stock (PLX) has performed as follows:
| Stock Metric | Value |
|---|---|
| Current Share Price | $1.45 |
| Market Capitalization | $105 million |
| 52-Week Range | $0.68 - $1.90 |
| Volume (Average) | 350,000 shares |
Conclusion of Mission Statement
Protalix BioTherapeutics, Inc. continues its commitment to innovation and accessibility in biotechnology while maintaining sustainable financial practices. The company's mission emphasizes the importance of developing treatments that are not only effective but also widely available to the patient population it serves.
How Protalix BioTherapeutics, Inc. (PLX) Works
Company Overview
Protalix BioTherapeutics, Inc. (PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins. The company utilizes its proprietary ProCellEx® platform for the production of biopharmaceuticals in plant cells. Protalix is primarily engaged in developing treatments for disorders such as Gaucher disease.
Business Model
Protalix operates a hybrid business model incorporating aspects of research and development, production, and commercialization. The company focuses on:
- Developing new therapeutics for rare diseases.
- Partnering with larger pharmaceutical firms for the marketing of their products.
- Generating revenue through sales of approved products.
Financial Overview
The financial performance of Protalix includes both revenue generation and expenditure management. As of Q2 2023, Protalix reported:
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue | $6.9 million |
| Net Loss | $3.3 million |
| Total Assets | $34.5 million |
| Total Liabilities | $10.2 million |
| Cash and Cash Equivalents | $23.1 million |
Pipeline and Product Development
Protalix is known for its pipeline targeting various diseases. As of September 2023, their pipeline includes:
| Product Candidate | Indication | Status |
|---|---|---|
| PRX-102 | Gaucher Disease | Commercialized |
| PRX-105 | Fabry Disease | In Clinical Trials |
| PRX-104 | Various Rare Diseases | Preclinical |
Key Partnerships
Protalix has established strategic partnerships to enhance its operational capacity. Notable collaborations include:
- Partnership with Chiesi Farmaceutici S.p.A. for the commercialization of PRX-102.
- Research collaborations with various academic institutions for pipeline development.
Market Performance
The company’s stock performance has shown various fluctuations. As of October 2023, the stock price was:
| Stock Metric | Amount |
|---|---|
| Current Share Price | $2.75 |
| Market Capitalization | $169 million |
| 52-week Range | $2.00 - $4.00 |
Research and Development Expenses
Investment in R&D is crucial for Protalix. For the fiscal year 2022, R&D expenses were reported as follows:
| Fiscal Year | R&D Expenses (USD) |
|---|---|
| 2022 | $8.0 million |
| 2021 | $7.5 million |
Regulatory Approvals
Protalix has received multiple regulatory approvals from varying agencies, including:
- FDA Approval for PRX-102 in 2021.
- EMA approval for market access in Europe.
Future Outlook
The future prospects for Protalix depend on the outcomes of ongoing clinical trials and market acceptance of their products. The company aims to expand its pipeline and enhance revenue through:
- New product launches.
- Identifying additional partnership opportunities.
How Protalix BioTherapeutics, Inc. (PLX) Makes Money
Revenue Streams
Revenue Streams
Protalix BioTherapeutics generates revenue primarily through the development and commercialization of biopharmaceutical products. The company’s revenue can mainly be categorized as follows:
- Product Sales
- Collaborative Agreements
- Research Grants
Product Sales
Protalix has developed and commercialized a drug, ELELYSO (taliglucerase alfa), for the treatment of Gaucher disease. According to the latest financial reports, Protalix reported product sales of approximately $5.5 million for the third quarter of 2023.
Collaborative Agreements
The company engages in collaborative agreements with larger pharmaceutical firms, which include upfront payments, milestone payments, and royalties on sales. An example is the agreement with Pfizer Inc., which is worth up to $18 million across various developmental stages. As of the latest quarter, Protalix recorded milestone revenue of $2 million from collaborative agreements.
Research Grants
Protalix also seeks funding through federal and private research grants to support its innovative therapies. For instance, they received a grant of $1.2 million from the National Institutes of Health (NIH) in 2023 for their research programs.
Financial Performance
In the latest financial results for Q3 2023, Protalix reported total revenues of approximately $8 million, which includes sales and collaboration revenue. The company's net loss for the same quarter was $4 million.
| Category | Q3 2023 Revenue (in millions) |
|---|---|
| Product Sales | $5.5 |
| Collaborative Agreements | $2.0 |
| Research Grants | $1.2 |
| Total Revenue | $8.0 |
| Net Loss | $4.0 |
Market Potential
Protalix is focusing on expanding its product pipeline, including therapies for various rare diseases, enhancing future revenue potential. The global market for enzyme replacement therapy is projected to reach over $7 billion by 2025, indicating a robust opportunity for the company.
Future Growth Strategies
Protalix plans to advance its pipeline of product candidates, including PRX-102 for Fabry disease, which is currently in clinical trials. Successful commercialization of this therapy could significantly impact revenue streams.
Investment and Funding
Protalix has also raised capital through various financing rounds, securing approximately $25 million in funding during a public offering in late 2022, aimed at supporting research and development efforts.
Protalix BioTherapeutics, Inc. (PLX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support